.png){kind=logo}
Stock image for illustration purposes only - book cover, edition or condition may vary.
Vascular Disruptive Agents for the Treatment of Cancer
Tim . Ed(S): Meyer
€ 193.86
FREE Delivery in Ireland
Description for Vascular Disruptive Agents for the Treatment of Cancer
Paperback. Vascular targeting is an expanding field. This book focuses on the destruction of existing tumour blood vessels with vascular disruptive agents (VDAs). Biomarkers and imaging modalities are examined, and a review of the development of key drugs is provided. Editor(s): Meyer, Tim. Num Pages: 265 pages, 7 colour tables, biography. BIC Classification: MJCL; MMG. Category: (G) General (US: Trade). Dimension: 235 x 155 x 14. Weight in Grams: 415.
Angiogenesis (formation of new vessels from pre-existing ones) is a crucial early event in the process of tumor development. New vessels supply the tumor with nutrients that are needed for further local growth and enable distant metastases (Folkman 1995). Judah Folkman (1971) highlighted the potential therapeutic imp- cations of tumor angiogenesis. He hypothesized that if tumor angiogenesis is inhibited, then tumor growth and metastasis will be impaired greatly or even impossible. The subsequent quest for endogenous and exogenous inhibitors of angiogenesis has yielded a variety of promising therapeutic agents that block one or more angiogenic pathways, a few of which ... Read more
Angiogenesis (formation of new vessels from pre-existing ones) is a crucial early event in the process of tumor development. New vessels supply the tumor with nutrients that are needed for further local growth and enable distant metastases (Folkman 1995). Judah Folkman (1971) highlighted the potential therapeutic imp- cations of tumor angiogenesis. He hypothesized that if tumor angiogenesis is inhibited, then tumor growth and metastasis will be impaired greatly or even impossible. The subsequent quest for endogenous and exogenous inhibitors of angiogenesis has yielded a variety of promising therapeutic agents that block one or more angiogenic pathways, a few of which ... Read more
Product Details
Format
Paperback
Publication date
2014
Publisher
Springer-Verlag New York Inc. United States
Number of pages
265
Condition
New
Number of Pages
256
Place of Publication
New York, United States
ISBN
9781489982261
SKU
V9781489982261
Shipping Time
Usually ships in 15 to 20 working days
Ref
99-15
About Tim . Ed(S): Meyer
Dr. Tim Meyer is a Senior Lecturer in Medical Oncology at the UCL Cancer Institute in London where he specialises in gastrointestinal cancers and drug development. He trained in medicine at UCL and obtained his PhD from London University, after which he completed specialist training in medical oncology. His major research focus is antibody-based vascular targeting.
Reviews for Vascular Disruptive Agents for the Treatment of Cancer